On probabilistic certification of combined cancer therapies using strongly uncertain models
From MaRDI portal
Publication:739722
DOI10.1016/J.JTBI.2015.08.008zbMATH Open1343.92205arXiv1502.06218OpenAlexW1936400706WikidataQ85955064 ScholiaQ85955064MaRDI QIDQ739722FDOQ739722
Publication date: 19 August 2016
Published in: Journal of Theoretical Biology (Search for Journal in Brave)
Abstract: This paper proposes a general framework for probabilistic certification of cancer therapies. The certification is defined in terms of two key issues which are the tumor contraction and the lower admissible bound on the circulating lymphocytes which is viewed as indicator of the patient health. The certification is viewed as the ability to guarantee with a predefined high probability the success of the therapy over a finite horizon despite of the unavoidable high uncertainties affecting the dynamic model that is used to compute the optimal scheduling of drugs injection. The certification paradigm can be viewed as a tool for tuning the treatment parameters and protocols as well as for getting a rational use of limited or expensive drugs. The proposed framework is illustrated using the specific problem of combined immunotherapy/chemotherapy of cancer.
Full work available at URL: https://arxiv.org/abs/1502.06218
Cites Work
- ACADO toolkit-An open-source framework for automatic control and dynamic optimization
- Constrained model predictive control: Stability and optimality
- Optimal scheduling of radiotherapy and angiogenic inhibitors
- On optimal delivery of combination therapy for tumors
- A Mathematical Tumor Model with Immune Resistance and Drug Therapy: An Optimal Control Approach
- AntiAngiogenic Therapy in Cancer Treatment as an Optimal Control Problem
- Angiogenesis inhibition and tumor-immune interactions with chemotherapy by a control set-valued method
- Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations
- Randomized methods for design of uncertain systems: sample complexity and sequential algorithms
- Application of optimal control theory to analysis of cancer chemotherapy regimens
- Mixed immunotherapy and chemotherapy of tumors: feedback design and model updating schemes
- Optimal solutions for a model of tumor anti-angiogenesis with a penalty on the cost of treatment
- Randomized Strategies for Probabilistic Solutions of Uncertain Feasibility and Optimization Problems
- The worst drug rule revisited: mathematical modeling of cyclic cancer treatments
- Title not available (Why is that?)
- Robust feedback design for combined therapy of cancer
Cited In (4)
- Learning-based sensitivity analysis and feedback design for drug delivery of mixed therapy of cancer in the presence of high model uncertainties
- Iterative method for estimating the robust domains of attraction of non-linear systems: application to cancer chemotherapy model with parametric uncertainties
- Probabilistic performance validation of deep learning‐based robust NMPC controllers
- Probabilistically certified region of attraction of a tumor growth model with combined chemo‐ and immunotherapy
Uses Software
This page was built for publication: On probabilistic certification of combined cancer therapies using strongly uncertain models
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q739722)
